Cure Cdkl5 Epilepsy Foundation

“Line 13 includes $14,000 paid to Unravel Biosciences for scientific services to generate datasets to support drug repurposing and potentially development. This represents the first payment, the second of which will be due in 2025.”

“Of the $192k raised in 2024, a single extraordinary contribution of $150,000 accounted for the majority of total support. This contribution was critical in launching the Foundation's mission but temporarily skews the public support calculation for this year. The Foundation also received contributions from a range of smaller donors and is actively expanding its donor base through ongoing fundraising initiatives. Because the public support test is measured over a rolling five-year period, the Foundation anticipates that future years will reflect a more balanced mix of contributions, bringing the organization well within the thresholds required to maintain public charity status.”

“In 2024, Cure CDKL5 Epilepsy Foundation completed its first full year of operations and raised $192k to advance research and treatment for CDKL5 Deficiency Disorder. The Foundation paid $14,000 to Unravel Biosciences for scientific research services directly supporting its exempt purpose. In addition, the Foundation established its grantmaking framework, identified research collaborators, and initiated planning for major grants to be awarded in 2025. These activities represent the Foundation's early programmatic work and reflect its mission to accelerate scientific discovery and therapeutic development for CDKL5 Deficiency Disorder.”